New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs Mazdutide

Vesugen vs Mazdutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
GLP-1 / Weight Loss Agonists
Mazdutide
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
Half-Life
Short (minutes); sustained gene-regulatory effects
~7 days
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
1.5 mg → 3 mg → 4.5 mg → 6 mg
Frequency
Daily for 10–30 days
Once weekly
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
  • Significant reduction in liver fat content (NAFLD/MASH potential)
  • Improves HbA1c and fasting glucose in type 2 diabetes
  • Favorable lipid profile changes (reduced triglycerides)
  • Once-weekly subcutaneous dosing
  • Potential for superior weight loss vs GLP-1 monotherapy
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Nausea
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +3 more
Stacks With